Myriad Genetics, Inc. (NASDAQ:MYGN) insider Nicole Lambert sold 4,354 shares of Myriad Genetics stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $19.73, for a total transaction of $85,904.42. Following the sale, the insider now owns 59,150 shares of the company’s stock, valued at $1,167,029.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of MYGN opened at $19.54 on Friday. The firm has a market cap of $1.48 billion, a P/E ratio of -54.28, a P/E/G ratio of 11.31 and a beta of 0.99. The stock has a 50 day simple moving average of $27.00 and a two-hundred day simple moving average of $28.22. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.86 and a quick ratio of 2.61. Myriad Genetics, Inc. has a 1 year low of $19.08 and a 1 year high of $48.40.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm had revenue of $195.10 million for the quarter, compared to the consensus estimate of $209.61 million. Myriad Genetics had a negative net margin of 3.22% and a positive return on equity of 5.42%. The business’s revenue was down 10.0% compared to the same quarter last year. During the same period last year, the firm posted $0.38 earnings per share. On average, equities analysts anticipate that Myriad Genetics, Inc. will post 0.15 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC raised its position in Myriad Genetics by 104.3% in the 4th quarter. Advisory Services Network LLC now owns 1,083 shares of the company’s stock worth $29,000 after purchasing an additional 553 shares during the period. Evoke Wealth LLC purchased a new position in shares of Myriad Genetics in the third quarter worth about $44,000. Meeder Asset Management Inc. purchased a new position in shares of Myriad Genetics in the third quarter worth about $52,000. First Bank & Trust increased its holdings in shares of Myriad Genetics by 583.7% in the fourth quarter. First Bank & Trust now owns 2,181 shares of the company’s stock worth $59,000 after buying an additional 1,862 shares during the period. Finally, Exchange Traded Concepts LLC bought a new stake in shares of Myriad Genetics in the 4th quarter valued at about $85,000.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Recommended Story: Why do analysts give a neutral rating?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.